EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro pharmacodynamics of the antimalarial drug cabamiquine

Claudia Demarta-Gatsi iD, Julia S Wallner, Satish K Dhingra, Sunil K Narwal iD, Vandana Thathy iD, Mohamed Maiga, Alhassane B Diallo, Maike Bonsen, Emilie Mathis, Ana Rita Gomes, Matthias Jacobs, Matthias Rottmann iD und 4 weitere

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.00802-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Claudia Demarta-Gatsi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Global Health R&D of Merck Healthcare, Ares Trading S.A. (a subsidiary of Merck KGaA, Darmstadt, Germany), Eysins, Switzerland. Hauptthemen laut MEDLINE: Antimalarials, Plasmodium falciparum, Aminoquinolines. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: healthcare business of Merck KGaA, Darmstadt, Germany, Chica and Heinz Schaller Foundation, European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Detailing the mode-of-action of novel antimalarial drugs is important to predict and optimize their treatment efficacy. To complement standardized in vivo studies, an in vitro pharmacodynamic characterization of the Plasmodium elongation factor 2 inhibitor cabamiquine has been undertaken on Plasmodium falciparum -infected red blood cells. Parasite growth arrest and killing kinetics were assessed using a MitoTracker assay, two genetically engineered luminescent parasite lines expressing firefly luciferase or NanoLuc (BRRoK assays), standard growth inhibition assays, and long-term live cell imaging. The results confirm that cabamiquine is a potent and fast-acting inhibitor of parasite protein translation, inducing complete arrest of the translational machinery within 6 h of drug exposure. Rate-of-kill assays showed a >100-fold difference in potency between the block on translation (luciferase-based BRRoK IC 50 = 0.9 nM) and overall parasite killing (6 h-treatment, ring-stage standard growth inhibition assay IC 50 > 100 nM), highlighting that translational arrest occurs well before parasite death. Prolonged inhibition of protein synthesis drives parasite exhaustion, followed by irreversible cell death within 48 h, preceding the parasite clearance observed in patients. These in vitro findings help contextualize why the clinically observed lag in parasite clearance may be temporally distinct from symptomatic improvement, including fever resolution. Here, cabamiquine presents itself as a fast-acting, slow clearing antimalarial drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsPlasmodium falciparumAminoquinolinesHumansErythrocytesProtein BiosynthesisAnimalsPeptide Elongation Factor 2

Stichwörter der Autor:innen

MitoTrackerPlasmodiumcabamiquinelive cell imagingluminescencepharmacodynamics

Substanzen

AntimalarialsAminoquinolinesPeptide Elongation Factor 2

Autor:innen und Institutionen

  • Global Health R&D of Merck Healthcare, Ares Trading S.A. (a subsidiary of Merck KGaA, Darmstadt, Germany), Eysins, Switzerland.
  • Centre for Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany.
  • Department of Microbiology & Immunology, Columbia University Irving Medical Center, New York, New York, USA.
  • Center for Malaria Therapeutics and Antimicrobial Resistance, Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Faculty of Pharmacy, Université des Sciences, des Techniques et des Technologies de Bamako (USTTB), Parasites and Microbes Research and Training Centre (PMRTC), Bamako, Mali.
  • LPHI, Université de Montpellier, CNRS, INSERM, Montpellier, France.

ORCID-Profile: Claudia Demarta-Gatsi, Sunil K Narwal, Vandana Thathy, Matthias Rottmann, Laurent Dembele, David A Fidock, Julien Guizetti, Thomas Spangenberg

Förderung

  • healthcare business of Merck KGaA, Darmstadt, Germany
  • Chica and Heinz Schaller Foundation
  • European Research Council
  • Agence Nationale de la Recherche

Zitieren

APA

Demarta-Gatsi, C., Wallner, J. S., Dhingra, S. K., Narwal, S. K., Thathy, V., Maiga, M., Diallo, A. B., Bonsen, M., Mathis, E., Gomes, A. R., Jacobs, M., Rottmann, M., Dembele, L., Fidock, D. A., Guizetti, J., & Spangenberg, T. (2026). In vitro pharmacodynamics of the antimalarial drug cabamiquine. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00802-26

Vancouver

Demarta-Gatsi C, Wallner JS, Dhingra SK, Narwal SK, Thathy V, Maiga M, et al. In vitro pharmacodynamics of the antimalarial drug cabamiquine. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.00802-26

BibTeX
@article{DemartaGatsi2026,
  author = {Demarta-Gatsi, Claudia and Wallner, Julia S and Dhingra, Satish K and Narwal, Sunil K and Thathy, Vandana and Maiga, Mohamed and Diallo, Alhassane B and Bonsen, Maike and Mathis, Emilie and Gomes, Ana Rita and Jacobs, Matthias and Rottmann, Matthias and Dembele, Laurent and Fidock, David A and Guizetti, Julien and Spangenberg, Thomas},
  title = {In vitro pharmacodynamics of the antimalarial drug cabamiquine},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.00802-26}
}
Kostenlos starten →